- Home
- ADD vs SCYX Comparison
ADD vs SCYX Comparison
Compare ADD & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADD
- SCYX
- Stock Information
- Founded
- ADD 2002
- SCYX 1999
- Country
- ADD United States
- SCYX United States
- Employees
- ADD N/A
- SCYX N/A
- Industry
- ADD Engineering & Construction
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- ADD Consumer Discretionary
- SCYX Health Care
- Exchange
- ADD Nasdaq
- SCYX Nasdaq
- Market Cap
- ADD 25.4M
- SCYX 28.5M
- IPO Year
- ADD N/A
- SCYX 2014
- Fundamental
- Price
- ADD $1.03
- SCYX $0.71
- Analyst Decision
- ADD
- SCYX
- Analyst Count
- ADD 0
- SCYX 0
- Target Price
- ADD N/A
- SCYX N/A
- AVG Volume (30 Days)
- ADD 451.7K
- SCYX 142.0K
- Earning Date
- ADD 06-25-2025
- SCYX 08-07-2025
- Dividend Yield
- ADD N/A
- SCYX N/A
- EPS Growth
- ADD N/A
- SCYX N/A
- EPS
- ADD N/A
- SCYX N/A
- Revenue
- ADD $1,770,000.00
- SCYX $2,630,000.00
- Revenue This Year
- ADD N/A
- SCYX $463.61
- Revenue Next Year
- ADD N/A
- SCYX $310.80
- P/E Ratio
- ADD N/A
- SCYX N/A
- Revenue Growth
- ADD 66.91
- SCYX N/A
- 52 Week Low
- ADD $0.56
- SCYX $0.66
- 52 Week High
- ADD $185.00
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- ADD 54.85
- SCYX 38.69
- Support Level
- ADD $0.87
- SCYX $0.67
- Resistance Level
- ADD $1.03
- SCYX $0.75
- Average True Range (ATR)
- ADD 0.09
- SCYX 0.04
- MACD
- ADD 0.01
- SCYX 0.00
- Stochastic Oscillator
- ADD 74.10
- SCYX 33.06
About ADD Color Star Technology Co. Ltd.
Color Star Technology Co Ltd is an entertainment technology company with a network that focuses on the application of technology and artificial intelligence in the entertainment industry. It provides online entertainment performances and online education through its wholly-owned subsidiaries Color Metaverse and CACM. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.